NCT00351858View on ClinicalTrials.gov

Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2006

Study Completion Date

February 28, 2009

Conditions
Breast NeoplasmsBreast Cancer
Interventions
DRUG

ertumaxomab

Trial Locations (1)

1000

Jules Bordet Institute, Free University of Brussels, Brussels

Sponsors

Lead Sponsor

Neovii Biotech
All Listed Sponsors
lead

Neovii Biotech

INDUSTRY